News Filter by: Industry Team AutomotiveEnergyFood & BeverageHealth Care Hospitality & LeisureLife SciencesManufacturingMaritime SportsTechnology Practice Area Corporate All CorporateEmployee Benefits & Executive CompensationEnvironmentalEstates & TrustsFinanceInsurance Private Equity & Venture CapitalReal EstateSecurities, Commodities & Exchange RegulationTaxationTransactions Government Solutions All Government SolutionsExport Controls & National SecurityFDA RegulatoryFederal & State Energy RegulatoryFreight & Commuter RailGovernment Procurement Immigration, Nationality & Consular LawNHTSA & Motor Vehicle SafetyPolitical LawPublic PolicyState Attorneys GeneralStrategic Communications Intellectual Property All Intellectual PropertyBusiness Method & Software PatentsChemical, Biotechnology & PharmaceuticalCybersecurityElectronicsGreen Energy TechnologiesIP Asset Management IP Due DiligenceIP LitigationMechanical & Electromechanical TechnologiesPatent Office TrialsTechnology Transactions & OutsourcingTrademark, Copyright & Advertising Counseling International All InternationalChinaEurope IsraelJapanMexico Litigation All LitigationAntitrustAppellateBankruptcy & Business ReorganizationsBusiness Litigation & Dispute ResolutionConstructionConsumer Law, Finance & Class Action Distribution & FranchiseGovernment Enforcement Defense & InvestigationsInsurance & Reinsurance LitigationLabor & EmploymentPrivacy, Security & Information ManagementSecurities Enforcement & LitigationTrade Secret Noncompete Litigation Office AustinBostonChicagoDallasDenverDetroitHoustonJacksonville Los AngelesMadisonMexico CityMiamiMilwaukeeNew YorkOrlandoSacramento San DiegoSan FranciscoSilicon ValleyTallahasseeTampaTokyoWashington, D.C. Topic Big DataCuba Foreign Corrupt Practices Act (FCPA)Health Care Reform Telemedicine In the News Press Releases Media Contact Jill Chanen Public Relations Manager jchanen foley.com 312.832.4745 123next 04 December 2018 Rosen Comments on Report That Found Flaws in FDA Drug Approval Process –Modern Healthcare Partner David Rosen was quoted in a Modern Healthcare article, "Federal investigation finds holes in orphan drug approval process," about an investigation by federal regulators that found fault with the U.S. Food and Drug Administration's process for approving so-called orphan drugs. 19 November 2018 Faget Comments on FDA Proposal to Streamline Premarket Review Submissions –MobiHealthNews Special Counsel Kyle Faget was quoted in a MobiHealthNews article, "Proposed framework lessens FDA's regulatory requirements for prescription drugs companion apps," about an FDA proposal that would classify most software released by pharmaceutical companies as "promotional labeling" not requiring premarket review. 18 October 2018 Beaver Comments on FDA Guidance Over Recalls –Inside Health Policy Partner Nathan Beaver was quoted in an Inside Health Policy article, "Food Industry Hopes FDA Is Judicious In Disclosing Retail Info In Recalls," about the FDA's recent guidance on disclosing food retailer information during certain recalls. 25 July 2018 Rosen Comments on FDA Plan to Facilitate Biosimilars –Regulatory Focus Partner David Rosen was quoted in an article in Regulatory Focus, “FDA Plans Hearing on Biosimilar Competition, Development,” about the U.S. Food and Drug Administration’s plan to hold a public hearing to gather input on how it can facilitate the development of biosimilars and help bring them to market in a timely fashion. 15 May 2018 Rosen Comments on Proposed Changes in FDA Drug-Device Rules –Bloomberg Law Partner David Rosen is quoted in a Bloomberg Law article, “Drug-Device Rules Could Give FDA Leg Up in Industry Fights,” about the FDA’s plan to revamp its rules on how to deal with overlapping drug, device and biologic products. 05 April 2018 Beaver Addresses Effect of New DOJ Policy on FDA Enforcement Actions –Food Quality & Safety Partner Nate Beaver was quoted in an article for Food Quality & Safety, “What DOJ’s Policy on FDA Guidance Really Means,” about the impact that a new Justice Department policy prohibiting government litigators in civil cases from using noncompliance with guidance documents to prove violations of federal law will have on FDA enforcement actions. 31 January 2018 Rosen Comments on Benefits of More FDA-Approved Generic Drugs –Health Care on Bloomberg Law Partner David Rosen was quoted in a Health Care on Bloomberg Law article, “Critics Say Trump’s Drug Price Talk Empty without Actions.” 18 January 2018 Rosen Quoted in Pink Sheet about New FDA Clinical Study Disclosure Program –Pink Sheet Partner David Rosen was quoted in a Pink Sheet article, “Clinical Study Disclosures Will Make Drug Reviews More Efficient- Gottlieb,” about the implications of a new FDA program linking drug approval documents to sponsors’ clinical study reports. 09 January 2018 Rosen Discusses Clinical Trial Consent Documents in Q&A –Clinical Leader Partner David Rosen was featured in a Clinical Leader Q&A, “Clinical Trial Deaths — Will Clearer Informed Consent Documents Be Enough?” 29 December 2017 Beaver Addresses FDA’s Planned New Guidance for Drug Developers –BNA Health Care Blog Partner Nathan Beaver was quoted in a BNA Health Care Blog article, ”FDA to Provide Earlier, Better Advice to Drug Developers,” about the FDA’s efforts to enhance its communications with drug suppliers as a way of lowering the cost of drug development. 123next Search News Filters applied: Search phrase entered: Sort results by: Most Recent Most Viewed Most Shared
04 December 2018 Rosen Comments on Report That Found Flaws in FDA Drug Approval Process –Modern Healthcare Partner David Rosen was quoted in a Modern Healthcare article, "Federal investigation finds holes in orphan drug approval process," about an investigation by federal regulators that found fault with the U.S. Food and Drug Administration's process for approving so-called orphan drugs.
19 November 2018 Faget Comments on FDA Proposal to Streamline Premarket Review Submissions –MobiHealthNews Special Counsel Kyle Faget was quoted in a MobiHealthNews article, "Proposed framework lessens FDA's regulatory requirements for prescription drugs companion apps," about an FDA proposal that would classify most software released by pharmaceutical companies as "promotional labeling" not requiring premarket review.
18 October 2018 Beaver Comments on FDA Guidance Over Recalls –Inside Health Policy Partner Nathan Beaver was quoted in an Inside Health Policy article, "Food Industry Hopes FDA Is Judicious In Disclosing Retail Info In Recalls," about the FDA's recent guidance on disclosing food retailer information during certain recalls.
25 July 2018 Rosen Comments on FDA Plan to Facilitate Biosimilars –Regulatory Focus Partner David Rosen was quoted in an article in Regulatory Focus, “FDA Plans Hearing on Biosimilar Competition, Development,” about the U.S. Food and Drug Administration’s plan to hold a public hearing to gather input on how it can facilitate the development of biosimilars and help bring them to market in a timely fashion.
15 May 2018 Rosen Comments on Proposed Changes in FDA Drug-Device Rules –Bloomberg Law Partner David Rosen is quoted in a Bloomberg Law article, “Drug-Device Rules Could Give FDA Leg Up in Industry Fights,” about the FDA’s plan to revamp its rules on how to deal with overlapping drug, device and biologic products.
05 April 2018 Beaver Addresses Effect of New DOJ Policy on FDA Enforcement Actions –Food Quality & Safety Partner Nate Beaver was quoted in an article for Food Quality & Safety, “What DOJ’s Policy on FDA Guidance Really Means,” about the impact that a new Justice Department policy prohibiting government litigators in civil cases from using noncompliance with guidance documents to prove violations of federal law will have on FDA enforcement actions.
31 January 2018 Rosen Comments on Benefits of More FDA-Approved Generic Drugs –Health Care on Bloomberg Law Partner David Rosen was quoted in a Health Care on Bloomberg Law article, “Critics Say Trump’s Drug Price Talk Empty without Actions.”
18 January 2018 Rosen Quoted in Pink Sheet about New FDA Clinical Study Disclosure Program –Pink Sheet Partner David Rosen was quoted in a Pink Sheet article, “Clinical Study Disclosures Will Make Drug Reviews More Efficient- Gottlieb,” about the implications of a new FDA program linking drug approval documents to sponsors’ clinical study reports.
09 January 2018 Rosen Discusses Clinical Trial Consent Documents in Q&A –Clinical Leader Partner David Rosen was featured in a Clinical Leader Q&A, “Clinical Trial Deaths — Will Clearer Informed Consent Documents Be Enough?”
29 December 2017 Beaver Addresses FDA’s Planned New Guidance for Drug Developers –BNA Health Care Blog Partner Nathan Beaver was quoted in a BNA Health Care Blog article, ”FDA to Provide Earlier, Better Advice to Drug Developers,” about the FDA’s efforts to enhance its communications with drug suppliers as a way of lowering the cost of drug development.